Developer docs
API playgroundTry for free, no card

Search company profiles

UroMems

Full company profile

uuid0000qi3

Namestring
UroMems
Legal namestring
UroMems SAS
Websiteurl
uromems.com
Company typeenum
Private
Founded yearint
2011
Descriptiontext

UroMems is a privately held medtech company founded in 2011 in Grenoble, France, with a U.S. headquarters in Minneapolis. The company is developing a single product, the UroActive® System — the first smart automated artificial urinary sphincter (AUS) intended to treat stress urinary incontinence (SUI) in both men and women. UroActive is powered by the company's proprietary MyoElectroMechanical System (MEMS) platform, which embeds micro-sensors, electronics, and algorithms inside the implant to continuously measure patient activity and automatically adjust urethral pressure without manual intervention. The device also includes a remote control interface allowing patients to manage voiding and pressure settings.

The UroActive System is currently investigational and not yet authorized for sale in any market. It has not received CE marking under EU MDR 2017/745 or FDA marketing authorization; however, in July 2025 the company received FDA Investigational Device Exemption (IDE) approval and French ANSM clearance to begin the SOPHIA2 pivotal clinical trial at 21 investigational centers across the U.S. and France. The company also holds FDA Safer Technologies Program (STeP) designation for the device. Once cleared, the intended go-to-market is direct hospital sales to urology and urogynecology departments, where trained surgeons would implant the device.

UroMems is pre-revenue and venture-funded. Cumulative disclosed funding exceeds $147 million across multiple equity rounds (notably a $47M Series C in June 2024 led by Crédit Mutuel Innovation, and a $60M strategic investment in May 2026 led by Ajax Health Fund I) plus a non-dilutive EIC Accelerator grant in late 2023. The company employs 60+ engineers and clinical specialists, holds 180+ patents/applications worldwide, and has built clinical partnerships with leading academic centers including La Pitié-Salpêtrière, Vanderbilt, Duke, and Mayo Clinic. Key board additions in 2024–2026 (Dan Rose as Chairman, Rinda Sama, and Ajax Health representatives) reflect investor positioning toward commercialization.

Short descriptiontext

UroMems is a French medtech company developing the UroActive® System, the first smart automated artificial urinary sphincter using its proprietary MEMS platform to treat stress urinary incontinence in men and women. The device is pre-commercial and currently in U.S. and European pivotal clinical trials.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersEybens, France
HQ citystring
Eybens
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
stress urinary incontinence treatment, smart implantable medical devices, artificial urinary sphincter, active medical implants, MEMS micro-system technology
Industry3 codes
PRIMARYHLAKAOAH
Reconstructive Urology & Urethral Stricture Care
SECONDARYHLAKAOAF
Endourology & Minimally Invasive Urologic Surgery
SECONDARYHLAKAOAA
General Urology
NAICS code2 codes
  • Surgical Appliance and Supplies Manufacturing339113
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code3 codes
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
  • Surgical & Medical Instruments & Apparatus3841
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Urological Medical Devices
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1UroActive Smart Implant Commercialization
TypeHardware Sales
Description

Pre-revenue medical device company developing UroActive, a smart automated artificial urinary sphincter for treating stress urinary incontinence. Revenue will be generated through device sales to hospitals and clinics once regulatory approvals are obtained in the U.S. and European markets. The product is not yet available for sale as it is under clinical evaluation.

uromems.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components2 values
Technology or R&D, Personnel
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1UroActive®
Description

The first smart automated artificial urinary sphincter (AUS) powered by MyoElectroMechanical System (MEMS) technology to treat stress urinary incontinence (SUI) in men and women.

uromems.com
Core offering1 text field

UroMems develops and plans to commercialize the UroActive System, the first smart automated artificial urinary sphincter (AUS) for treating stress urinary incontinence (SUI) in men and women. Powered by the company's proprietary MyoElectroMechanical System (MEMS) platform, the implant is placed around the urethral duct and automatically adjusts urethral pressure in real time based on patient activity measured by embedded micro-sensors. The device is currently under clinical investigation and has not yet received marketing authorization in the U.S. or EU.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • All 6 male feasibility study patients showed devices operating as expected with no need for revision nor explant for 7-15 months
+3 more records
Product overview1 text field

UroMems is a single-product company developing the UroActive® System, the first smart automated artificial urinary sphincter (AUS) for treating stress urinary incontinence (SUI) in both men and women. The device is powered by a proprietary MyoElectroMechanical System (MEMS) technology platform that combines embedded smart, AI-based, digital and robotic systems. The UroActive System automatically adjusts urethral pressure based on real-time patient activity data collected by micro-sensors, creating personalized treatment algorithms for each patient. The product is currently under clinical investigation and has not received marketing authorization from FDA or EU regulators.

Product and service1 record
1UroActive System
CategorySmart Implantable Urological Medical Device
Description

The UroActive System is the first smart automated artificial urinary sphincter (AUS) powered by UroMems' proprietary MyoElectroMechanical System (MEMS) technology, designed to treat stress urinary incontinence in men and women. The implant is placed around the urethral duct and automatically adjusts urethral pressure in real time based on patient activity measured by embedded micro-sensors, eliminating the need for manual adjustments and reducing tissue damage from constant pressure. The system is intended for adult patients with SUI and is operated by an intuitive patient remote control.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-07-17
Description

Co-principal U.S. investigator site for SOPHIA2 pivotal trial with Dr. Melissa Kaufman serving as principal investigator.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-07-17
Description

Co-principal U.S. investigator site for SOPHIA2 pivotal trial with Dr. Drew Peterson serving as principal investigator.

3La Pitié-Salpêtrière University Hospital
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Key clinical trial site for first-in-human and first-in-female UroActive implants. Professor Emmanuel Chartier-Kastler serves as principal investigator and clinical advisor.

uromems.com
4Nantes University Hospital
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical trial site for first-in-man study of UroActive System.

uromems.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Axonics (acquired by Boston Scientific)
TypeDirect peer
Description

Axonics developed sacral neuromodulation implants for urge/overflow incontinence and fecal incontinence before being acquired by Boston Scientific in 2024 for ~$3.7B. Closest analog to UroMems as a venture-backed, single-indication implantable incontinence company that achieved breakthrough scale and was acquired by a strategic - UroMems' near-term trajectory (pivotal trial, ASP positioning, BSX as potential acquirer) closely mirrors Axonics' pre-acquisition arc.

TypeBroad incumbent
Description

Boston Scientific owns the AMS 800 artificial urinary sphincter - the entrenched gold-standard AUS for male SUI - as well as Axonics' SNM systems for urge incontinence. As the dominant incumbent and the party most likely to either acquire UroMems or launch a defensive next-gen AUS, it is the central strategic reference point for UroMems' market opportunity.

TypeDirect peer
Description

Laborie is a private-equity-owned urology-focused medtech company (backed by Patricia Industries/Investor AB) with deep presence in urodynamics, pelvic floor, and male incontinence diagnostics and devices. It is a direct competitor profile as a urology-specialty company selling to the same urologist and urogynecologist call points that UroMems is targeting.

TypeDirect peer
Description

Caldera Medical is a venture-backed women's health medtech focused on surgical solutions for stress urinary incontinence and pelvic organ prolapse (mesh and biologic implants). It serves the same female-SUI patient pool with a surgical-urology approach, making it one of the most relevant direct peers for UroMems' targeted female SUI indication.

TypeBroad incumbent
Description

Coloplast is a global incumbent in continence care, with a large portfolio of urinary catheters, external collection devices, and surgical sling products, plus a substantial sales force calling on urologists. While it does not currently offer an active AUS, it is the reference incumbent UroMems must disintermediate in the hospital channel.

6Cook Medical
TypeBroad incumbent
Description

Cook Medical is a privately held diversified medtech with a dedicated urology specialty business (including ureteral stents, stone management, and continence products). The breadth of its urology portfolio and its physician relationships make it a comparable broad-urology incumbent that could enter the smart-AUS category or be a potential strategic acquirer.

TypeBroad incumbent
Description

Ethicon, J&J's surgical franchise, markets mid-urethral sling meshes and other pelvic floor repair products for female SUI. As a large medtech incumbent with the channel and clinical footprint to scale a competing SUI device, it is a key broader competitor and potential acquirer of UroMems.

TypeBroad incumbent
Description

Convatec is a global medtech with a Continence Care business unit selling catheters, ostomy, and continence products. While focused on disposable rather than active implantable solutions, it is a relevant strategic comparable in the broader urinary-incontinence treatment ecosystem and a potential adjacent acquirer.

TypeBroad incumbent
Description

B. Braun is a diversified European medtech with a significant urology franchise (Uromed catheters, Ureofix, and other continence/intermittent catheter products). It shares UroMems' European medtech heritage and is a relevant comparable for urology product portfolio strategies and European commercialization paths.

TypeEmerging player
Description

Atlantic Therapeutics is an emerging player selling INNOVO, a non-invasive electrical muscle stimulation device for SUI. Although it targets a different point on the treatment pathway (conservative therapy rather than surgical AUS), it competes for the same SUI patient population and represents an alternative-technology emerging competitor.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors17 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

UroMems

Urological Medical Devicesuromems.com

UroMems is a French medtech company developing the UroActive® System, the first smart automated artificial urinary sphincter using its proprietary MEMS platform to treat stress urinary incontinence in men and women. The device is pre-commercial and currently in U.S. and European pivotal clinical trials.

What UroMems does

UroMems is a privately held medtech company founded in 2011 in Grenoble, France, with a U.S. headquarters in Minneapolis. The company is developing a single product, the UroActive® System — the first smart automated artificial urinary sphincter (AUS) intended to treat stress urinary incontinence (SUI) in both men and women. UroActive is powered by the company's proprietary MyoElectroMechanical System (MEMS) platform, which embeds micro-sensors, electronics, and algorithms inside the implant to continuously measure patient activity and automatically adjust urethral pressure without manual intervention. The device also includes a remote control interface allowing patients to manage voiding and pressure settings.

The UroActive System is currently investigational and not yet authorized for sale in any market. It has not received CE marking under EU MDR 2017/745 or FDA marketing authorization; however, in July 2025 the company received FDA Investigational Device Exemption (IDE) approval and French ANSM clearance to begin the SOPHIA2 pivotal clinical trial at 21 investigational centers across the U.S. and France. The company also holds FDA Safer Technologies Program (STeP) designation for the device. Once cleared, the intended go-to-market is direct hospital sales to urology and urogynecology departments, where trained surgeons would implant the device.

UroMems is pre-revenue and venture-funded. Cumulative disclosed funding exceeds $147 million across multiple equity rounds (notably a $47M Series C in June 2024 led by Crédit Mutuel Innovation, and a $60M strategic investment in May 2026 led by Ajax Health Fund I) plus a non-dilutive EIC Accelerator grant in late 2023. The company employs 60+ engineers and clinical specialists, holds 180+ patents/applications worldwide, and has built clinical partnerships with leading academic centers including La Pitié-Salpêtrière, Vanderbilt, Duke, and Mayo Clinic. Key board additions in 2024–2026 (Dan Rose as Chairman, Rinda Sama, and Ajax Health representatives) reflect investor positioning toward commercialization.

UroMems firmographics

Firmographics
Name
UroMems
Legal name
UroMems SAS
Website
https://uromems.com
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
51–100 employees
Short description
UroMems is a French medtech company developing the UroActive® System, the first smart automated artificial urinary sphincter using its proprietary MEMS platform to treat stress urinary incontinence in men and women. The device is pre-commercial and currently in U.S. and European pivotal clinical trials.
Ownership category
akta.pro rank

UroMems industry classification

Industry
Product category
Urological Medical Devices
NAICS
Surgical Appliance and Supplies Manufacturing (339113), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAKAOAH
Reconstructive Urology & Urethral Stricture Care
SECONDARYHLAKAOAF
Endourology & Minimally Invasive Urologic Surgery
SECONDARYHLAKAOAA
General Urology

Keywords

  • Stress urinary incontinence treatment
  • Smart implantable medical devices
  • Artificial urinary sphincter
  • Active medical implants
  • MEMS micro-system technology

Where UroMems is headquartered

Location

Headquarters

HQ city
Eybens
HQ country
France
HQ region
Europe

Offices2 records

Markets served

UroMems business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel

Revenue model

  1. UroActive Smart Implant Commercialization: Pre-revenue medical device company developing UroActive, a smart automated artificial urinary sphincter for treating stress urinary incontinence. Revenue will be generated through device sales to hospitals and clinics once regulatory approvals are obtained in the U.S. and European markets. The product is not yet available for sale as it is under clinical evaluation.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

UroMems product offering

Product offering

Core offering

UroMems develops and plans to commercialize the UroActive System, the first smart automated artificial urinary sphincter (AUS) for treating stress urinary incontinence (SUI) in men and women. Powered by the company's proprietary MyoElectroMechanical System (MEMS) platform, the implant is placed around the urethral duct and automatically adjusts urethral pressure in real time based on patient activity measured by embedded micro-sensors. The device is currently under clinical investigation and has not yet received marketing authorization in the U.S. or EU.

Product overview

UroMems is a single-product company developing the UroActive® System, the first smart automated artificial urinary sphincter (AUS) for treating stress urinary incontinence (SUI) in both men and women. The device is powered by a proprietary MyoElectroMechanical System (MEMS) technology platform that combines embedded smart, AI-based, digital and robotic systems. The UroActive System automatically adjusts urethral pressure based on real-time patient activity data collected by micro-sensors, creating personalized treatment algorithms for each patient. The product is currently under clinical investigation and has not received marketing authorization from FDA or EU regulators.

Differentiator

Problem solved

Functional benefit

Brands

  • UroActive®: The first smart automated artificial urinary sphincter (AUS) powered by MyoElectroMechanical System (MEMS) technology to treat stress urinary incontinence (SUI) in men and women.

Products and services

  • UroActive System The UroActive System is the first smart automated artificial urinary sphincter (AUS) powered by UroMems' proprietary MyoElectroMechanical System (MEMS) technology, designed to treat stress urinary incontinence in men and women. The implant is placed around the urethral duct and automatically adjusts urethral pressure in real time based on patient activity measured by embedded micro-sensors, eliminating the need for manual adjustments and reducing tissue damage from constant pressure. The system is intended for adult patients with SUI and is operated by an intuitive patient remote control.

Quantifiable outcome

  • All 6 male feasibility study patients showed devices operating as expected with no need for revision nor explant for 7-15 months
  • +3 more outcomes

Companies that use UroMems

Customer profile

Named customers6 records

Segments3 records

Ideal customer profiles1 record

UroMems technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

UroMems partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • Vanderbilt UniversitycoreStrategic or Co-development Partner · 17 July 2025Co-principal U.S. investigator site for SOPHIA2 pivotal trial with Dr. Melissa Kaufman serving as principal investigator.
  • Duke UniversitycoreStrategic or Co-development Partner · 17 July 2025Co-principal U.S. investigator site for SOPHIA2 pivotal trial with Dr. Drew Peterson serving as principal investigator.
  • La Pitié-Salpêtrière University HospitalcoreStrategic or Co-development PartnerKey clinical trial site for first-in-human and first-in-female UroActive implants. Professor Emmanuel Chartier-Kastler serves as principal investigator and clinical advisor.
  • Nantes University HospitalcoreStrategic or Co-development PartnerClinical trial site for first-in-man study of UroActive System.

Scale indicators9 records

Recent moves6 records

Expansion highlights5 records

UroMems competitors and assessment

Company assessment

Direct peers

  • Axonics (acquired by Boston Scientific): Axonics developed sacral neuromodulation implants for urge/overflow incontinence and fecal incontinence before being acquired by Boston Scientific in 2024 for ~$3.7B. Closest analog to UroMems as a venture-backed, single-indication implantable incontinence company that achieved breakthrough scale and was acquired by a strategic - UroMems' near-term trajectory (pivotal trial, ASP positioning, BSX as potential acquirer) closely mirrors Axonics' pre-acquisition arc.
  • Laborie Medical Technologies: Laborie is a private-equity-owned urology-focused medtech company (backed by Patricia Industries/Investor AB) with deep presence in urodynamics, pelvic floor, and male incontinence diagnostics and devices. It is a direct competitor profile as a urology-specialty company selling to the same urologist and urogynecologist call points that UroMems is targeting.
  • Caldera Medical: Caldera Medical is a venture-backed women's health medtech focused on surgical solutions for stress urinary incontinence and pelvic organ prolapse (mesh and biologic implants). It serves the same female-SUI patient pool with a surgical-urology approach, making it one of the most relevant direct peers for UroMems' targeted female SUI indication.

Broad incumbents

  • Boston Scientific: Boston Scientific owns the AMS 800 artificial urinary sphincter - the entrenched gold-standard AUS for male SUI - as well as Axonics' SNM systems for urge incontinence. As the dominant incumbent and the party most likely to either acquire UroMems or launch a defensive next-gen AUS, it is the central strategic reference point for UroMems' market opportunity.
  • Coloplast: Coloplast is a global incumbent in continence care, with a large portfolio of urinary catheters, external collection devices, and surgical sling products, plus a substantial sales force calling on urologists. While it does not currently offer an active AUS, it is the reference incumbent UroMems must disintermediate in the hospital channel.
  • Cook Medical: Cook Medical is a privately held diversified medtech with a dedicated urology specialty business (including ureteral stents, stone management, and continence products). The breadth of its urology portfolio and its physician relationships make it a comparable broad-urology incumbent that could enter the smart-AUS category or be a potential strategic acquirer.
  • Ethicon (Johnson & Johnson): Ethicon, J&J's surgical franchise, markets mid-urethral sling meshes and other pelvic floor repair products for female SUI. As a large medtech incumbent with the channel and clinical footprint to scale a competing SUI device, it is a key broader competitor and potential acquirer of UroMems.
  • Convatec: Convatec is a global medtech with a Continence Care business unit selling catheters, ostomy, and continence products. While focused on disposable rather than active implantable solutions, it is a relevant strategic comparable in the broader urinary-incontinence treatment ecosystem and a potential adjacent acquirer.
  • B. Braun Melsungen: B. Braun is a diversified European medtech with a significant urology franchise (Uromed catheters, Ureofix, and other continence/intermittent catheter products). It shares UroMems' European medtech heritage and is a relevant comparable for urology product portfolio strategies and European commercialization paths.

Emerging players

  • Atlantic Therapeutics: Atlantic Therapeutics is an emerging player selling INNOVO, a non-invasive electrical muscle stimulation device for SUI. Although it targets a different point on the treatment pathway (conservative therapy rather than surgical AUS), it competes for the same SUI patient population and represents an alternative-technology emerging competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

UroMems social profiles

Digital presence

UroMems compliance and trust

Trust signal

Compliance4 records

UroMems financial estimates

Financial estimate

Revenue estimate

Valuation estimate

UroMems leadership team

Management profile

Number of profiles

Profiles15 records

UroMems funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors17 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

UroMems M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about UroMems

What does UroMems do?

UroMems develops and plans to commercialize the UroActive System, the first smart automated artificial urinary sphincter (AUS) for treating stress urinary incontinence (SUI) in men and women. Powered by the company's proprietary MyoElectroMechanical System (MEMS) platform, the implant is placed around the urethral duct and automatically adjusts urethral pressure in real time based on patient activity measured by embedded micro-sensors. The device is currently under clinical investigation and has not yet received marketing authorization in the U.S. or EU.

Is UroMems a public or private company?

UroMems is a private company. It is classified as venture growth investor backed and is currently operating.

When was UroMems founded?

UroMems was founded in 2011. It employs 51 to 100 people.

Where is UroMems based?

UroMems is headquartered in Eybens, France, in the Europe region.

How does UroMems make money?

One revenue line is on record: uroActive Smart Implant Commercialization.

Who are UroMems's main competitors?

Direct peers on record are Axonics (acquired by Boston Scientific), Laborie Medical Technologies and Caldera Medical. Broad incumbents are Boston Scientific, Coloplast, Cook Medical, Ethicon (Johnson & Johnson), Convatec and B. Braun Melsungen. Atlantic Therapeutics is listed as an emerging player.

Does UroMems have an API?

No public API is recorded for UroMems.

What industry is UroMems in?

UroMems's product category is Urological Medical Devices. Its primary akta.pro industry code is HLAKAOAH, Reconstructive Urology & Urethral Stricture Care, with a secondary code of HLAKAOAF, Endourology & Minimally Invasive Urologic Surgery. Its NAICS code is 339113 and its SIC code is 3842.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Pulse 2.0UroMems: $60 Million Raised For Smart Implant Treating Stress Urinary IncontinenceUroMems announced a $60 million strategic investment from Ajax Health Fund I to fund pivotal clinical trials and prepare for commercial launch of the UroActive System, a smart automated implant for treating stress urinary incontinence. The financing, the largest fundraising round to date for UroMems, will support the ongoing SOPHIA2 clinical trial across 21 investigational centers in the U.S. and France as the company seeks regulatory approvals in both markets. UroActive, which uses MyoElectroMechanical System technology to automatically adapt to patient activity, has not yet received marketing authorization from the FDA or EU regulators.Tech Funding NewsFrench startup UroMems secures $60M from Ajax Health for next-gen urinary incontinence implant — TFNUroMems raised $60 million from Ajax Health Fund I, its largest round, to fund clinical trials of its UroActive implant in the U.S. and France. The automated artificial urinary sphincter treats stress urinary incontinence without manual adjustments, and the financing supports the SOPHIA2 trial across 21 centers.InvestorsinhealthcareFrance: Ajax Health invests US$60m in UroMems in support of clinical trials in US and FranceUroMems, a France-based company developing implantable mechatronics for stress urinary incontinence, raised US$60m from US PE firm Ajax Health. The investment is the largest to date and will support clinical trials in the US and France.VentureburnUroMems Raises $60M for Smart Urology Implant TrialsUroMems raised $60 million in a strategic round from Ajax Health Fund I, its largest funding to date, bringing total capital over $150 million. The funds will support the SOPHIA2 pivotal trial for its UroActive smart urinary sphincter, with data due December 2026. The company aims to submit FDA PMA and CE Mark applications.FinSMEsUroMems Raises $60M in FundingUroMems, a French developer of implantable mechatronics for stress urinary incontinence, raised $60M in strategic funding from Ajax Health Fund I. The funds will support pivotal clinical trials of its UroActive implant across 21 centers in the U.S. and France. The company holds over 200 granted patents and is enrolling patients in ongoing trials.MassDeviceUroMems raises $60M to support clinical trials for smart urology implantUroMems, a Grenoble, France–based medtech startup with U.S. headquarters in Minneapolis, raised a $60 million strategic investment from Ajax Health Fund I to support its ongoing SOPHIA2 clinical trial and prepare for commercial launch of its UroActive smart automated artificial urinary sphincter. The device, which uses a myoelectromechanical system with microsensors to automatically adjust urethral pressure based on patient activity, has received FDA investigational device exemption (IDE) and is being evaluated at 21 investigational centers in the U.S. and France for regulatory submissions to the FDA and European regulators.PR NewswireUroMems Raises $60 Million Strategic Investment from U.S.-Based Ajax Health Fund IUroMems, a medtech company based in Grenoble, France, has raised a $60 million strategic investment from Ajax Health Fund I, the largest fundraising round to date for the company. The funding will support pivotal clinical trials of the UroActive® System, the first smart automated artificial urinary sphincter to treat stress urinary incontinence, at 21 investigational centers across the U.S. and France. The resulting clinical data will support regulatory submissions to both U.S. and European markets, bringing the company closer to commercialization of the device.UtvUroMems Raises $60 Million Strategic Investment from U.S.-Based Ajax Health Fund IUroMems raised $60 million in a strategic investment from Ajax Health Fund I, its largest round to date. The capital will fund pivotal clinical trials of the UroActive implant in the U.S. and France, supporting regulatory submission to both markets. The company expects to complete the SOPHIA2 trial in 21 centers.UromemsUroMems Raises $60 Million Strategic Investment from U.S.-Based Ajax Health Fund IUroMems raised $60 million in a strategic investment from Ajax Health Fund I, its largest round to date. The capital will fund pivotal clinical trials of the UroActive implant in the U.S. and France, supporting regulatory submissions. The company aims to advance toward FDA PMA submission and commercialization.openPR.comThe Global Stress Urinary Incontinence Devices Market Size is growing at a CAGR of 6.53% by 2034, estimates DelveInsightUroMems received investigational device exemption (IDE) approval from the U.S. FDA and ANSM clearance in France in July 2025, enabling a pivotal clinical trial for its UroActive smart implant to treat stress urinary incontinence in men. Affluent Medical separately announced the completion of its pilot phase for the Artus artificial urinary sphincter in January 2025. The global stress urinary incontinence devices market is projected to grow from USD 2,232.79 million in 2025 to USD 3,929.46 million by 2034, at a CAGR of 6.53%.